EUVIMEDEUVIMED entdecken
Open Access

Patient Experiences With GLP-1 Receptor Agonists

Isabella de Vere Hunt, Mariana Ramirez-Posada, Christopher Sam Babu, Cati Brown-Johnson, Eleni Linos, Fatima Rodriguez

JAMA Network Open · 05.06.2026 · 9 (6) · e2616951

DOI: 10.1001/jamanetworkopen.2026.16951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.06.2026. Verfasst von Isabella de Vere Hunt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are transformational therapies in the treatment of obesity; yet discontinuation rates are high, and patients experience rapid weight regain after stopping treatment. Few scientific publications have reported patients’ experiences of taking GLP-1 RAs in a variety of health contexts outside its use as treatment for type 2 diabetes.

Objective

To provide insight into the lived experiences of patients taking GLP-1 RAs to inform optimal long-term weight management treatment. Design, Setting, and Participants This qualitative study used inductive thematic analysis of semistructured video interviews conducted between July 22 and September 10, 2025, with participants from 15 US states. Participants included adults who were taking or had previously taken GLP-1 RAs for any treatment indication, recruited through ResearchMatch and snowball sampling. Main Outcomes and Measures Themes identified through inductive thematic analysis.

Results

Of 30 participants, 10 self-identified as men, 1 as nonbinary, and 19 as women; their mean (SD) age was 54.0 (8.8) years. A total of 23 participants were using a GLP-1 RA at time of interview, and 7 participants had stopped GLP-1 RA use. Eight key themes were extracted and categorized into 2 overarching domains. The first domain was patient-reported benefits and trade-offs. It comprised the following themes: (1) reduction in food noise, psychological hunger, or appetite; (2) GLP-1 RAs are not a standalone weight loss solution; (3) wide spectrum of adverse effects experienced; and (4) patients prepared to withstand substantial adverse effects and logistical challenges to achieve weight loss. The second domain was social, clinical, and structural context. It comprised the following themes: (5) perceived stigma associated with taking GLP-1 RAs, influenced by primary indication for prescription; (6) information provision and clinical support are essential but highly variable; (7) access challenges and cost can be prohibitive; and (8) value of shared experiences. Conclusions and Relevance In this qualitative study of patient experiences with GLP-1 receptor agonists, participants described GLP-1 RA therapy functioning as a facilitator rather than a replacement for lifestyle change, emphasizing the need for behavioral interventions alongside pharmacotherapy to sustain treatment benefits. Quality of care was highly variable; thus, standardized guidelines for patient education and clinical support could improve expectation management around likely adverse effects and long-term management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsObesityFemaleHumansMaleMiddle AgedQualitative ResearchSemaglutideUnited States

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
  • Stanford Center for Digital Health, Department of Medicine, Stanford University, Stanford, California.
  • Department of Dermatology, School of Medicine, Stanford University, Stanford, California.
  • Stanford Internal Medicine, Department of Medicine, Stanford University, Stanford, California.
  • Evaluation Sciences Unit, Division of Primary Care and Population Health, Department of Medicine, School of Medicine, Stanford University, Palo Alto, California.
  • Division of Cardiovascular Medicine and the Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, California.

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

de Vere Hunt, I., Ramirez-Posada, M., Babu, C. S., Brown-Johnson, C., Linos, E., & Rodriguez, F. (2026). Patient Experiences With GLP-1 Receptor Agonists. JAMA Network Open, 9(6), e2616951. https://doi.org/10.1001/jamanetworkopen.2026.16951

Vancouver

de Vere Hunt I, Ramirez-Posada M, Babu CS, Brown-Johnson C, Linos E, Rodriguez F. Patient Experiences With GLP-1 Receptor Agonists. JAMA Network Open. 2026;9(6):e2616951. doi:10.1001/jamanetworkopen.2026.16951

BibTeX
@article{deVereHunt2026,
  author = {de Vere Hunt, Isabella and Ramirez-Posada, Mariana and Babu, Christopher Sam and Brown-Johnson, Cati and Linos, Eleni and Rodriguez, Fatima},
  title = {Patient Experiences With GLP-1 Receptor Agonists},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {6},
  pages = {e2616951},
  doi = {10.1001/jamanetworkopen.2026.16951}
}
Kostenlos starten →